Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the 2026 AHA/ASA Guideline for Adult Stroke Rehabilitation and Recovery!
Quiz|Articles|November 15, 2026 (Updated: September 23, 2026)
NeurologyLive® Brain Games: November 15, 2026
Author(s)Louie Pasculli
Listen
0:00 / 0:00
Key Takeaways
- A weekly Sunday-morning quiz format delivers three clinician-authored questions that blend clinical and historical neurology topics.
- Core content areas span Alzheimer disease/dementia, epilepsy, headache/migraine, movement disorders, multiple sclerosis, neuromuscular and sleep disorders, and stroke/cerebrovascular disease.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is National Epilepsy Awareness Month!
Advertisement
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topics, written by physicians, clinicians, and experts in the fields of neurological care and advocacy.
Test your mettle each week with 3 questions that cover a variety of aspects in the field of neurology, with a focus on dementia and Alzheimer disease, epilepsy and seizure disorders, headache and migraine, movement disorders, multiple sclerosis, neuromuscular disorders, sleep disorders, and stroke and cerebrovascular disease.
This week's questions includes the theme of National Epilepsy Awareness Month!
Interested in submitting quiz questions? Contact our editor, Marco Meglio, via email:
In 1937, Tracy Putnam and H. Houston Merritt identified the anticonvulsant activity of phenytoin (then called diphenylhydantoin). Which experimental approach led to this discovery?
The 2025 International League Against Epilepsy (ILAE) updated classification of epileptic seizures made which change from the 2017 framework?
In March 2022, the FDA approved ganaxolone (Ztalmy). Which statement best describes the drug and its approved indication?
How did you do on this week's quiz? Let us know with a response to the poll below. Don't forget to share and compare your results with your friends!
How many questions did you get correct?
Advertisement
Related to this article
Nick Cunniffe, MD, PhD, assistant professor and consultant neurologist at the University of Cambridge, discusses lessons from a decade of proof-of-concept remyelination trials in MS.
As diabetes drugs are tested for repurposing in Alzheimer disease, the negative phase 3 EVOKE and EVOKE+ results for oral semaglutide have moved attention toward prevention and earlier, combination-based approaches.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 13, 2026.
At a NeurologyLive Clinical Forum in Philadelphia, Chafic Karam, MD, chief of neuromuscular medicine at Penn Medicine, discussed treatment sequencing in myasthenia gravis.
The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]
Robert Bermel, MD, discusses advances in disease-modifying therapies, the challenges of monitoring MS progression, and emerging biomarkers and treatments that may address remaining unmet needs.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 3 NIMBLE Trial: Cemdisiran Efficacy and Safety Results in gMG
2
FDA Requires NAION Warning Across GLP-1 Receptor Agonist Class
3
Myelin Repair Research in MS: Lessons From Clinical Trials and the Road Ahead
4
From Glucose to Cognition: Where Repurposed Diabetes Drugs Stand in Alzheimer Disease
5